Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Recruiting 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Squamous Cell Carcinoma of Head and Neck 5Skin Neoplasms 5Neoplasm Metastasis 5Melanoma 5Lung Neoplasms 5Carcinoma 5Recurrence 4Neoplasms 4Mouth Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Adenocarcinoma 3Ovarian Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Laryngeal Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Squamous Cell 2Vaccinia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumors 1

Interventions

pembrolizumab 57Nivolumab 51Ipilimumab 31Specimen Handling 23Magnetic Resonance Spectroscopy 19Cyclophosphamide 14Biopsy 11fludarabine 10binimetinib 10Opdualag 10trametinib 9relatlimab 9Radiosurgery 9CTLA-4 Antigen 9dabrafenib 8lifileucel 7fludarabine phosphate 7aldesleukin 7encorafenib 6Interleukin-2 6cemiplimab 5atezolizumab 5Paclitaxel 5Blood Specimen Collection 5X-Rays 4Taxes 4Pemetrexed 4Gemcitabine 4Cisplatin 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Melanoma × cemiplimab × 90 days × Clear all
NCT07527325 2026-06-05

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

University of California, Irvine

Phase 2 Not yet recruiting
35 enrolled
Dermatologic

Melanoma

NCT06246916 2026-05-06

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Regeneron Pharmaceuticals

Phase 3 Recruiting
560 enrolled
Dermatologic

Melanoma

NCT06413680 2026-04-28

BrILliance

Regeneron Pharmaceuticals

Phase 1/2 Recruiting
240 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT05352672 2026-04-22

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
1,546 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT07511036 2026-04-06

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
20 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡